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ABSTRACT
We present a case of an 85-year-old woman diagnosed with uncomplicated pyelonephritis, who was treated with intravenous ceftriaxone. 
Her chronic medications were phenprocoumon, diltiazem and bisoprolol. During the infectious phase, the patient presented tachycardia 
– despite high-dose beta-blocker treatment – and developed left acute heart failure, with acute renal failure (pre-renal origin). After 
introduction of furosemide diuretic therapy, clinical conditions improved and better control of the volemic status and heart rate was 
achieved. Several days after ceftriaxone and digoxin therapy initiation, worsening multiple non-blanching palpable purpuric lesions with 
bullae and papules, limited to the lower extremities, were noted. Skin biopsy was performed and a diagnosis of leucocytoclastic vasculitis, with 
associated panniculitis, was made. Ceftriaxone was discontinued and systemic corticosteroids were introduced, with a clear improvement 
in the cutaneous condition.
LEARNING POINTS
•	 Leucocytoclastic	vasculitis	is	a	rare	but	significant	side	effect	related	to	the	administration	of	ceftriaxone.
• The importance of skin biopsy in the differential diagnosis of skin eruptions.
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CASE DESCRIPTION
An	85-year-old	woman,	with	known	permanent	atrial	fibrillation,	moderate	mitral	insufficiency	and	chronic	renal	failure,	presented	to	the	
Emergency Room after an accidental fall. Her chronic medications were phenprocoumon (for at least 7 years), diltiazem and bisoprolol. The 
patient	reported	dysuria.	Haematological	examination	showed	leucocytosis	and	increased	inflammatory	markers.	The	urinary	sediment	was	
pathologic (leucocyturia, bacteriuria). The urinary culture was positive for multi-sensitive Escherichia coli. Abdominal CT showed dilatation 
in the right pyelocalyceal cavities. Uncomplicated pyelonephritis was diagnosed, and intravenous antibiotic therapy with ceftriaxone was 
started.
During the infectious phase, the patient presented tachycardia (up to 160 bpm), despite high-dose treatment with beta blockers. She 
developed left acute heart failure, with acute on chronic renal failure (pre-renal origin). After introduction of diuretic therapy with 
furosemide, clinical conditions improved and better control of the volemic status and heart rate was achieved.
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Four and 5 days, respectively, following ceftriaxone and digoxin therapy initiation, worsening multiple non-blanching palpable purpuric 
lesions with bullae and papules, limited to the lower extremities, were noted (Fig. 1). Skin biopsy was performed and a diagnosis of 
leucocytoclastic vasculitis, with associated panniculitis, was made (Fig. 2).
Ceftriaxone was discontinued (after 7 days of therapy) and systemic corticosteroids were introduced, with a clear improvement in the 
cutaneous condition.
Figure 1. Leucocytoclastic 
vasculitis in the lower legs
Figure 2. Skin biopsy. A: Panoramic view with severe vasculitis, B: detailed vascular structure and C: deep dermis and hypodermis tissue, with another vessel affected by vasculitis
DISCUSSION
In our case, the most interesting aspect was the diagnostic challenge before the skin biopsy result. A systemic vasculitis was excluded; 
immunological	blood	tests	did	not	yield	any	significant	results.
We considered a drug reaction: digoxin and ceftriaxone were started after hospital admission concomitant with skin lesion appearance, but 
the clinical features were more suggestive of phenprocoumon involvement.
The	 first	 clinical	 suspicion	was	 “late-onset	warfarin-induced	 skin	 necrosis”,	 a	 rare	 complication	 of	 therapy	with	warfarin	 and	 coumarin	
derivatives. It usually appears 3 to 6 days after initiation of therapy, but cases of late onset have been reported. A drug-associated recurrent 
skin necrosis in a 57-year-old patient was described with phenprocoumon[1]. The time of late onset, in case series, is from 15 days to 4 
years[2]. This hypothesis did not appear to completely align with our patient’s clinical features, as, independently of the time of onset, typical 
warfarin-induced skin necrosis manifestations are purpuric areas that have evolved into large, tender haemoserous bullae, which break 
down to form ulcers.
The second clinical suspicion was that ceftriaxone may have acted to enhance the anticoagulant effects of the vitamin K antagonist by 
cephalosporin-associated	platelet	inhibition	and	by	decreasing	the	gastrointestinal	tract	flora.	Our	patient,	moreover,	had	an	inadequate	
diet,	without	the	required	vitamin	K	intake.	The	INR	increased	to	6.1	concomitantly	with	skin	lesion	appearance.
We	 finally	 considered	 the	 hypothesis	 of	 a	 reaction	 due	 to	 recently	 introduced	 drugs:	 digoxin	 has	 not	 been	 shown	 to	 produce	 similar	
reactions[3], whereas ceftriaxone-induced leucocytoclastic vasculitis has been described[3].
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